26905-02-2

Basic information

• Product Name: 4-(4-CHLOROPHENYL)PIPERIDINE
• Synonyms: 4-(4-CHLOROPHENYL)PIPERIDINE;Piperidine, 4-(4-chlorophenyl)-
• CAS NO: 26905-02-2
• Molecular Formula: C₁₁H₁₄ClN
• Molecular Weight: 195.69
• Mol File: 26905-02-2.mol
• Article Data: 18

Chemical Properties

• Melting Point: 0°C
• Boiling Point: 0°C
• Flash Point: 0°C
• Appearance: /
• Density: 1.095 g/cm³
• Vapor Pressure: 0.00204mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C(protect from light)
• Solubility: soluble in Methanol
• PKA: 10.14±0.10(Predicted)
• CAS DataBase Reference: 4-(4-CHLOROPHENYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-CHLOROPHENYL)PIPERIDINE(26905-02-2)
• EPA Substance Registry System: 4-(4-CHLOROPHENYL)PIPERIDINE(26905-02-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 26905-02-2(Hazardous Substances Data)

Usage

General Description

4-(4-chlorophenyl)piperidine is a chemical compound with the molecular formula C11H14ClN. It belongs to the class of substituted piperidines, which are commonly used as building blocks in organic synthesis and as pharmaceutical intermediates. The compound is a white to pale yellow solid with a melting point of 56-59°C and a boiling point of 296-298°C. It is soluble in organic solvents such as ethanol, methanol, and chloroform but relatively insoluble in water. 4-(4-chlorophenyl)piperidine has potential applications in the field of medicinal chemistry and has been studied for its potential use in the treatment of neurological and psychiatric disorders.

InChI:InChI=1/C11H14ClN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2

Upstream product

• 694-05-3 1,2,3,6-tetrahydropyridine 
• 108-90-7 chlorobenzene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 106-39-8 bromochlorobenzene 
• 1679-18-1 4-Chlorophenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 946593-11-9 tert-butyl 4-(4-chlorophenyl)piperidine-1-carboxylate 
• 637-87-6 1-Chloro-4-iodobenzene 
• 235109-63-4 4-(4-chloro-phenyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1143575-84-1 2-chloro-N-(tetrahydro-2H-pyran-4-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine 
• 1143575-85-2 (2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-yl)-(tetrahydropyran-4-yl)-amine 
• 1143575-87-4 [1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-cyclopropyl]-methanol 
• 1146361-96-7 (R)-1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-1-(4-fluorophenyl)-2-methylpropan-2-ol 

Downstream Products

• 1189532-94-2 2-(4-(4-chlorophenyl)piperidin-1-yl)-8-hydroxynaphthalene-1,4-dione 
• 1261171-55-4 C₁₉H₂₁ClN₂O₂ 
• 1426521-19-8 C₁₈H₂₁ClN₂ 
• 1334721-16-2 6-chloro-N-(4-(4-(4-chlorophenyl)piperidin-1-yl)benzyl)-2-ethylimidazo[1,2-a]pyridine-3-carboxamide 
• 1334721-19-5 7-chloro-N-(4-(4-(4-chlorophenyl)piperidin-1-yl)benzyl)-2-ethylimidazo[1,2-a]pyridine-3-carboxamide 
• 1613627-55-6 C₁₈H₁₇ClN₂ 
• 1427469-45-1 2-(4-(4-chlorophenyl)piperidin-1-yl)-8-nitro-6-(tri-fluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 
• 946580-54-7 C₂₅H₃₀ClFN₂O₂ 
• 1403664-51-6 (S)-2-amino-1-(4-(4-chlorophenyl)piperidin-1-yl)-3-methylbutan-1-one 

Relevant articles and documents

TRPML MODULATORS

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.